U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for …
WEB1 day ago · NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency) without factor VIII (FVIII) inhibitors, or ...
US FDA approves Pfizer's drug for rare bleeding disorder
WEB1 day ago · Oct 11 (Reuters) - The U.S. Food and Drug Administration approved Pfizer's (PFE.N), opens new tab once-a-week injection for the two main types of a rare bleeding disorder called hemophilia, the ...
Pfizer’s TALZENNA ® in Combination with XTANDI - Business Wire
WEB2 days ago · A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and in its subsequent reports on Form 10-Q ...
Pfizer’s Hympavzi Approved for Treatment of Certain Types of …
WEB1 day ago · The Food and Drug Administration approved Pfizer ’s PFE -1.04% Hympavzi to prevent or reduce bleeding episodes in patients with certain kinds of hemophilia, the pharmaceutical company said. The ...
Press Releases - Pfizer
WEB4 days ago · Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age. 08.12.2024.
Pfizer chief Albert Bourla to meet activist investor Starboard
WEB3 days ago · Pfizer’s lead independent director, Shantanu Narayen, is expected to accompany Bourla, one person said. In an unusual twist, two of Pfizer’s top former executives are working with Starboard.
FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines …
WEBAug 22, 2024 · The updated mRNA COVID-19 vaccines include Comirnaty and Spikevax, both of which are approved for individuals 12 years of age and older, and the Moderna COVID-19 Vaccine and Pfizer-BioNTech COVID...
Pfizer wins FDA nod for hemophilia B drug that will be first once ...
WEB1 day ago · Pfizer wins FDA approval for hemophilia B drug that will be first once-weekly treatment The news is expected to help patients avoid painful intravenous infusions or injections
Pfizer to Showcase Scientific Advancements in Respiratory and …
WEB3 days ago · NEW YORK, October 08, 2024--Pfizer Inc. (NYSE: PFE) will present data across its infectious disease portfolio at the upcoming IDWeek 2024 congress, held in Los Angeles from October 16-19, 2024 ...
Pfizer rolls out another cost-cutting program, sets $1.5 billion …
WEBMay 22, 2024 · U.S. drugmaker Pfizer on Wednesday launched a new multi-year program to reduce its expenses by about $1.5 billion by the end of 2027, adding on to a $4 billion cost cutting plan it announced last...